Hey, sharkey1...you know how Nasrat gets attacked for not making PRs on things like intended fillings, etc? Well, here is something to consider. J&J announced this TODAY...
Johnson & Johnson (JNJ) intends to file applications for 14 new drugs by 2025, with average peak sales of $4B for each of them, a company executive tells Reuters.
And the reaction on the stock? It is DOWN 1/2 a percent. Perhaps investors should contemplate that before attacking Elite and Nasrat for the manipulated share price that they cannot control.